*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from The University of Texas MD Anderson Cancer Center (MDACC) and the Moffitt Cancer Center and Research Institute (MCC).1

A total of 76 patients progressed, with 47 continuing with osimertinib treatment. These patients exhibited a median second progression-free survival (PFS2) of 12.6 months. Continuation of osimertinib beyond progression was also associated with a longer overall survival (OS) compared with discontinuation (11.2 vs 6.1 months, P = .02).

Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), has demonstrated efficacy against both classical epidermal growth factor receptor (EGFR)-sensitizing mutations and EGFR resistance T790M mutations. Yet, despite its increasing role in NSCLC, data regarding resistance mechanisms to this agent are limited. In the study, Xiuning Le, MD, PhD, and colleagues said that gaining a comprehensive understanding of resistance mechanisms to osimertinib is needed if strategies to overcome resistance are to be successful. Read more.